• linkedin
  • Increase Font
  • Sharebar

    TRT and heart health: Conflicting findings published

    Five recently published studies, including four from the National Institutes of Health-supported large-scale Testosterone Trials, provide new insight on testosterone replacement therapy’s effect on cardiovascular health, as well as anemia, cognitive function, and volumetric bone density and strength.

    The effect of TRT on cardiovascular health in men with hypogonadism has been an unresolved issue considering the conflicting findings and design limitations of available research. Two of the new studies generated differing results, and while both studies had notable strengths, they had important weaknesses as well.

    The Cardiovascular Trial of the Testosterone Trials (TTrials) was a prospective, randomized, double-blind, placebo-controlled study that included 170 men aged 65 years and older with hypogonadal symptoms and low testosterone (<275 ng/dL) appearing to be age-related. Participants were randomized to use testosterone gel or placebo gel for 1 year.

    Noncalcified coronary artery plaque volume determined by coronary computed tomographic angiography, a surrogate for coronary atherosclerosis, was investigated as the primary endpoint. Data from 138 men who completed the study showed the median plaque volume increased significantly more in the TRT-treated men compared with the control group (204 mm3 to 232 mm3 vs 317 mm3 to 325 mm3; estimated difference, 41 mm3, p=.003) (JAMA 2017; 317:708-16). Compared with controls, the TRT-treated group also had a significantly greater increase in total plaque volume, but there was no difference between groups in the change in coronary artery calcium score.

    Related - Testosterone therapy's big week: One urologist's perspective

    “The strengths of the trial include its prospective, randomized design, selection of men with unequivocally low testosterone, and high retention rate. However, it used surrogate outcomes for cardiovascular events and was not of sufficient size or duration to investigate risk of major adverse cardiovascular events,” said J. Kellogg Parsons, MD, MHS, of the University of California, San Diego, an investigator for the TTrials and a coauthor for previously published TTrials research. “Larger studies are needed to understand the clinical implications of the radiologic findings.”

    Separately, researchers from Kaiser Permanente California analyzed cardiovascular event rates in a cohort of men age ≥40 years who had documented androgen deficiency (coded diagnosis or morning serum total testosterone <300 ng/dL). They compared men who had been dispensed a prescription for any form of TRT (n=8,808) and those who were never dispensed TRT (n=35,527). In the TRT group, men had a mean age of 58.4 years, 1.4% had a history of a cardiovascular event, and median follow-up was 4.2 years. Men who never received TRT had a mean age of 59.8 years, 2.0% had a prior cardiovascular event, and median follow-up was 3.2 years.

    Multivariable Cox proportional hazard analysis using propensity score methodology to balance baseline characteristics found a 33% significantly reduced risk (p<.001) for the primary outcome (composite cardiovascular endpoint including acute myocardial infarction, coronary revascularization, unstable angina, stroke, transient ischemic attack, and sudden cardiac death) in the TRT group compared with controls (JAMA Intern Med, epub., Feb. 21, 2017). The result was similar in additional analyses comparing risks for all but one of the individual events and in subgroups of men <65 years, ≥65 years, with a cardiovascular event history, without a cardiovascular event history, and looking at defined follow-up intervals.

    T. Craig Cheetham, PharmD, MS, of Southern California Permanente Medical Group’s department of research and evaluation, Pasadena, is lead author of the paper, which was not part of the TTrials. He told Urology Times, “Our findings suggest that TRT is safe in androgen-deficient males. However, based on findings from previous studies, we believe caution is warranted when treating frail elderly males and those with high cardiovascular risk.”

    Commenting on the study design, Dr. Cheetham noted that its relatively large cohort of androgen-deficient men treated with TRT represents its major strength. In addition, the TRT-treated group was well matched to the control group, and the results were robust in the planned stratified and sensitivity analyses.

    However, he acknowledged that because it was an observational study, the reported data only identify associations and cannot determine cause and effect. In addition, the study could not control for potential bias from unmeasured confounding.

    Next: Dr. Burnett discusses findings

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results